Monday, July 15, 2019 - Gilead Scientific, maker of the HIV prevention drugs Truvada and Descovy has an enormous vested interest in seeing that Descovy receives FDA approval. Truvada broken bones lawyer representing individuals and families of individuals harmed by Truvada's negligence and corporate greed and have a long track record of success in winning cases against multinational pharmaceutical conglomerates.
Descovy is Gilead's HIV prevention drug of the future and the company claims it is not only more effective in preventing the transmission of HIV, but also has less adverse side effects pertaining to bone density loss and renal complications and kidney failure. Gilead charges over $1500 per month for the daily treatment which is going off patent in the coming months. Without a seamless switch to Descovy, generic drugs will be able to flood the market at a fraction of Truvada's cost and erode Gilead's market share. Gilead recently cut a deal with the Trump administration to provide 2.4 million bottles of Truvada free of charge to those needing the drug regardless of their economic status, in exchange for keeping effectively keeping the generic competition off of the market while transitioning to Descovy. Members in Congress feel that the deal's arrangement could unduly influence the Trump FDA to approve Descovy without adequate pre-market testing. Gilead cites the free market system for allowing them to charge the exorbitant prices as an incentive for drugmakers to take on the high risks of drug development. Again Congress disagrees as the discovery and implementation of Truvada was by Gilead scientists funded with government grant money. Congresswoman Alexandria Ortiz feels that the US taxpayer is Truvada's true patent owner and that the drug should be given to everyone for free. Arguments like the ones being made may be moot, however, as a consortium of major drug companies have banded together to come up with what they feel is an even more effective drug for preventing the spread of HIV. It should be noted that Descovy has not received FDA approval as of the time of this writing.
According to PharmaPhorum.com, another, more effective, HIV prevention drug is about to come to market that could turn the treatment of HIV into a more competitive situation as well as make it easier patients. "ViiV, a joint venture between majority owner GlaxoSmithKline, Pfizer, and Shionogi, has data showing that its two-drug regimen is able to suppress the disease after switching from a triple regimen including drugs such as Gilead's Truvada." Results of a recent study show that the group's HIV suppressant drug Dovato (dolutegravir+lamivudine) was able to prevent the spread of the virus for 48 weeks after switching from Truvada. Dovato can be taken less often then Truvada as it unfolds and releases into the stomach more slowly. Wikipedia describes this new company specializing in HIV treatment. "ViiV Healthcare is a pharmaceutical company specialising in the development of therapies for HIV infection that was created as a joint venture by Pfizer and GlaxoSmithKline in November 2009 with both companies transferring their HIV assets to the new company. In 2012 Shionogi joined the company."
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.